&lt;p&gt;Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date&lt;/p&gt;

Zavras, Phaedon D.; Wang, Yiyang; Gandhi, Arpita; Lontos, Konstantinos; Delgoffe, Greg M.

doi:10.2147/ott.s177844

Cited by 6 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chimeric antigen receptor T-cell (CAR T) therapy has emerged as a new treatment paradigm with demonstrable improvements in outcomes compared to historic data from salvage chemoimmunotherapy (e.g., complete response rates of 58% for axi-cel in ZUMA-1 [18], 40% for tisa-cel in JULIET trial [19,20], versus 7% for salvage chemotherapy in SCHOLAR-1 [21]). CAR T therapies target the antigens expressed by malignant and non- Administration to treat r/r LBCL after ≥2 prior systemic therapies [22,23].…”

Section: Introductionmentioning

confidence: 99%

Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States

Liu

Oluwole

Diakité

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

To assess from a US payer perspective the cost-effectiveness of the chimeric antigen receptor T (CAR T)-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) following ≥2 systemic therapy lines. Methods A 3-state (i.e., pre-progression, post-progression, death) partitioned survival model was used to estimate the quality-adjusted life-years (QALYs) and costs for patients on each treatment over a lifetime horizon. Progression-free survival (PFS) and overall survival (OS) were based on a matchingadjusted indirect treatment comparison (MAIC) that accounted for differences in trial population baseline characteristics. Mixture-cure models (MCMs) were used to account for long-term survivors. Costs included drug acquisition and administration for the CAR T-cell therapies and conditioning chemotherapy, apheresis, CAR T-specific monitoring, transplant, hospitalization, adverse events, routine care, and terminal care. Health state utilities were derived from trial and published data. Sensitivity analyses included probabilistic sensitivity analyses (PSAs) and an analysis of extremes that assessed the results across a vast array of combinations of parametric OS and PFS curves across the 2 therapies. Results Compared to tisa-cel, axi-cel resulted in 2.31 QALYs gained

show abstract

Section: Introductionmentioning

confidence: 99%

Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States

Liu

Oluwole

Diakité

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…Using the patient's own T cells as a starting point, CAR-T cells are genetically modified to combine the extracellular antigen recognition domain of an antibody with the intracellular signaling domain of the T cell receptor (TCR). In the case of tisagenlecleucel, this antigen recognition domain is an scFv derived from the mouse monoclonal antibody FMC63, which specifically binds human CD19 in its native conformation [72]. This domain is in turn linked to the TCR domain by transmembrane and spacer domains, which give its added flexibility to optimally engage CD19-expressing cancer cells.…”

Section: Tisagenlecleucel (Novartis)mentioning

confidence: 99%

Immunotherapies for pediatric cancer: current landscape and future perspectives

Hutzen

Paudel

Kararoudi

et al. 2019

Cancer Metastasis Rev

View full text Add to dashboard Cite

The advent of immunotherapy has revolutionized how we manage and treat cancer. While the majority of immunotherapy-related studies performed to date have focused on adult malignancies, a handful of these therapies have also recently found success within the pediatric space. In this review, we examine the immunotherapeutic agents that have achieved the approval of the US Food and Drug Administration for treating childhood cancers, highlighting their development, mechanisms of action, and the lessons learned from the seminal clinical trials that ultimately led to their approval. We also shine a spotlight on several emerging immunotherapeutic modalities that we believe are poised to have a positive impact on the treatment of pediatric malignancies in the near future.

show abstract